Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 10/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940638 | 0.83 | NCF1 (0.44) | GRM4ADORA2A | |
| SCHEMBL15940574 | 0.82 | ADORA2A (0.54) | GRM4GRM5ADORA2ACYP1A2CYP3A4 | |
| SCHEMBL15941009 | 0.82 | FADS1 (0.49) | GRM5EGFRADORA2ACYP1A2 | |
| SCHEMBL15940633 | 0.82 | FFAR1 (0.39) | GRM5EGFRADORA2A | |
| SCHEMBL15947627 | 0.80 | NCF1 (0.54) | ADORA2ACYP1A2CYP3A4 | |
| SCHEMBL20593899 | 0.77 | NCF1 (0.41) | GRM4ADORA2ACYP1A2 | |
| SCHEMBL30018921 | 0.77 | NCF1 (0.41) | GRM4ADORA2ACYP1A2 | |
| SCHEMBL15940617 | 0.76 | NCF1 (0.43) | GRM4GRM5ADORA2ACYP1A2 | |
| SCHEMBL12125704 | 0.76 | AAK1 (0.40) | CA12CA2CA9GRM5CA1 | |
| SCHEMBL21858037 | 0.74 | ADORA2A (0.41) | ADORA2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | claimed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | claimed |
| CN-104955809-B | The purposes of substituted acetylene-derivative and its positive allosteric modulators as mGluR4 | 普雷斯特威克化学公司 | 2018-12-11 | — | — | CN | disclosed |
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2953933-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014121883-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | CA12 3697/4885CA2 2292/4885CA9 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.